Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial

Table 1 Baseline characteristics of the study population: patients with at least 6 months OS (N = 361)

	CoC-Group (N = 251)	non-CoC-Group (N = 110)
Median age, years (range; interquartile range)	63 (30–83; 56.1–68.7)	65 (40–86; 56.4–71.5)
Sex
Male	164 (65%)	77 (70%)
Female	87 (35%)	33 (30%)
WHO status
0	139 (55%)	63 (57%)
1	90 (36%)	40 (36%)
2	2 (1%)	2 (2%)
Missing data	20 (8%)	5 (5%)
Therapy arm
Capecitabine	127 (51%)	53 (48%)
5-FU	124 (49%)	57 (52%)
Cohort
Adjuvant	182 (73%)	36 (33%)
Neoadjuvant	69 (27%)	74 (67%)
Tumour category^a
T1 or T2	48 (19%)	12 (11%)
T3	184 (73%)	89 (81%)
T4	18 (7%)	8 (7%)
Missing data	1 (< 1%)	1 (1%)
Nodal category^a
Node negative	93 (37%)	45 (41%)
Node positive	157 (63%)	60 (54%)
Missing data	1 (< 1%)	5 (5%)

Data are n (%) or median (range). ^aclinical or pathological category. WHO World Health Organization, FU fluorouracil. T - size or direct extent of the primary tumor